BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $252,127,335 | -13.8% | 4,946,583 | -8.9% | 5.28% | -18.9% |
| Q3 2022 | $292,444,000 | -20.9% | 5,429,702 | -5.7% | 6.51% | -11.4% |
| Q2 2022 | $369,852,000 | -2.2% | 5,758,247 | +18.1% | 7.34% | +8.5% |
| Q1 2022 | $378,153,000 | +7.9% | 4,876,877 | +19.4% | 6.77% | +9.7% |
| Q4 2021 | $350,589,000 | -1.2% | 4,084,218 | -7.5% | 6.17% | -5.1% |
| Q3 2021 | $354,953,000 | +24.5% | 4,413,191 | +24.6% | 6.50% | +27.9% |
| Q2 2021 | $285,125,000 | +29.4% | 3,541,919 | +35.6% | 5.08% | +23.5% |
| Q1 2021 | $220,369,000 | +226.6% | 2,612,868 | +210.7% | 4.12% | +216.4% |
| Q4 2020 | $67,468,000 | +508.5% | 840,832 | +509.9% | 1.30% | +400.4% |
| Q3 2020 | $11,087,000 | +3269.9% | 137,865 | +3510.9% | 0.26% | +2788.9% |
| Q2 2020 | $329,000 | +12.7% | 3,818 | +6.3% | 0.01% | -10.0% |
| Q1 2020 | $292,000 | -68.4% | 3,593 | -67.5% | 0.01% | -66.7% |
| Q4 2019 | $925,000 | -84.8% | 11,060 | -84.1% | 0.03% | -86.9% |
| Q3 2019 | $6,075,000 | -39.9% | 69,455 | -43.7% | 0.23% | -46.5% |
| Q2 2019 | $10,104,000 | -58.8% | 123,365 | -59.1% | 0.43% | -66.4% |
| Q1 2019 | $24,543,000 | -10.3% | 301,847 | -27.4% | 1.27% | -30.9% |
| Q4 2018 | $27,356,000 | – | 415,619 | – | 1.84% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |